Latest Global Manufacturing News

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Amanda Lacaze, the CEO who transformed Lynas Rare Earths from a struggling startup to an ASX50 powerhouse, has announced her retirement. The company is now searching for a new leader to guide its next growth phase.

Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.

6K Additive, Inc. launches a fully underwritten A$48 million IPO on the ASX, aiming to scale its innovative scrap-based metal powder production for additive manufacturing. The capital raise supports a major capacity expansion backed by a US Department of Defense grant.

Papyrus Australia has secured a $4.2 million contract to manufacture biodegradable Collar Keeper® products for the mining sector, marking its shift from R&D to commercial production. The agreement with TBS Mining Solutions sets the stage for sustainable innovation in mining operations.

Orica Limited has delivered its strongest financial performance in over a decade, driven by premium product demand and digital innovation, while advancing ambitious sustainability targets. The company signals continued growth for 2026 despite emerging supply chain challenges.

Orica Limited reported a 6% increase in revenue to AUD 8.14 billion and a 23% rise in EBIT to AUD 992.2 million for FY2025, alongside record safety performance and significant strides in decarbonisation.

Titomic Limited has launched a major European manufacturing hub and a UK subsidiary, secured a $50 million capital raise, and forged strategic partnerships to advance its cold spray additive manufacturing technology.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Arafura Rare Earths has received conditional approval for a US$100 million equity investment from Export Finance Australia, reinforcing the strategic importance of its Nolans Project in Australia’s critical minerals landscape.

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.